1757 related articles for article (PubMed ID: 11522637)
1. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
2. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
3. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
4. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus.
Ohashi M; Kanai F; Tateishi K; Taniguchi H; Marignani PA; Yoshida Y; Shiratori Y; Hamada H; Omata M
Biochem Biophys Res Commun; 2001 Mar; 282(2):529-35. PubMed ID: 11401492
[TBL] [Abstract][Full Text] [Related]
5. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
6. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
7. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
Mao CY; Hua HJ; Chen P; Yu DC; Cao J; Teng LS
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):282-7. PubMed ID: 19502169
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
9. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.
Vollmer CM; Ribas A; Butterfield LH; Dissette VB; Andrews KJ; Eilber FC; Montejo LD; Chen AY; Hu B; Glaspy JA; McBride WH; Economou JS
Cancer Res; 1999 Sep; 59(17):4369-74. PubMed ID: 10485485
[TBL] [Abstract][Full Text] [Related]
10. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
[TBL] [Abstract][Full Text] [Related]
11. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene.
Kanai F; Shiratori Y; Yoshida Y; Wakimoto H; Hamada H; Kanegae Y; Saito I; Nakabayashi H; Tamaoki T; Tanaka T; Lan KH; Kato N; Shiina S; Omata M
Hepatology; 1996 Jun; 23(6):1359-68. PubMed ID: 8675152
[TBL] [Abstract][Full Text] [Related]
15. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.
Takahashi M; Sato T; Sagawa T; Lu Y; Sato Y; Iyama S; Yamada Y; Fukaura J; Takahashi S; Miyanishi K; Yamashita T; Sasaki K; Kogawa K; Hamada H; Kato J; Niitsu Y
Mol Ther; 2002 May; 5(5 Pt 1):627-34. PubMed ID: 11991754
[TBL] [Abstract][Full Text] [Related]
16. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
Maemondo M; Saijo Y; Narumi K; Kikuchi T; Usui K; Tazawa R; Matsumoto K; Nakamura T; Sasaki K; Takahashi M; Niitsu Y; Nukiwa T
Cancer Res; 2004 Jul; 64(13):4611-20. PubMed ID: 15231673
[TBL] [Abstract][Full Text] [Related]
18. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
[TBL] [Abstract][Full Text] [Related]
20. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
Yun CO; Kim E; Koo T; Kim H; Lee YS; Kim JH
Cancer Gene Ther; 2005 Jan; 12(1):61-71. PubMed ID: 15375379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]